CARDIAC MONITORING IN HER-2 POSITIVE ELDERLY PATIENTS TREATED WITH TRANSTUZUMAB

An Article Review By Dr. Rajani Sinha, India
(MBBS, MMSc in Oncology Student of Texila American University)
Email:- dr.rajanisinha@yahoo.com

SOURCE

KEYWORDS
Cardiotoxicity, Transtuzumab, HER -2 over expression, Breast Cancer, Elderly

INTRODUCTION
Human epidermal growth factor receptor -2 (HER-2) is a member of EGFR (epidermal growth factor receptor) family, plays a very significant role in cell growth and proliferation [1] HER – 2 protein is over expressed in 20% of breast cancer and is associated within aggressive course, poor prognosis and response to treatment [2-3]. The introduction of transtuzumab, a monoclonal antibody directed against, the extra cellular domain of HER - 2 receptor, has revolutionized the treatment of HER – 2 positive early breast cancer and has led to significant improvement in disease free survival and overall survival over chemotherapy alone.

In randomized multicenter trials with HER – 2 over expressing metastatic breast cancer patients, addition of transtuzumab to first line chemotherapy has improved objective response rate, the time to disease progression and overall survival over chemotherapy alone [4,5]. Hence transtummbab is now considered as the standard of care for all patients who over amplify HER – 2 neu receptors.
These benefits have come with the cost of increased risk of cardiotoxicity. Transtuzumab related cardiotoxicity is mediated by interruption of normal HER – 2 signaling pathway in the heart, which is responsible for maintenance of normal growth, repair and survival of cardiomyocytes. Cardiotoxicity related to transtuzumab is different from that of anthracyclins as it is not dose related and appears to be largely reversible on discontinuation of therapy. There is no alteration in ultra structural abnormalities whereas that due to anthracyclins are caused by free radical induced oxidative stress to cardiac muscles cells [12].

REVIEW OF LITERATURE

In the pivotal metastatic Breast Cancer trials cardiac dysfunction was seen in the patient treated with transtuzumab and chemotherapy. The incidence was greatest among the patients who received concurrent anthracyclins. The findings led to design the subsequent transtuzumab trials which included prospective monitoring of cardiac effects and protocols for its management. The risk of cardio toxicity also driven efforts to develop non-anthracyclin based regimens for HER – 2 positive breast cancer patients.

Four major adjuvant trials: HERA (herceptin adjuvant trial), NSABP-B31 trial, the national surgical adjuvant breast and bowel project, (N CCTG) N 9831 trial, the North Central Cancer Treatment Group and (BCIRG) 006 trial, the Breast Cancer International Research Group investigated various adjuvant approaches with transtuzumab. More than 13000 women enrolled were HER-2 positive. Results indicated that adjuvant transtuzumab reduces recurrence by nearly 50% and increases overall survival by 33% therefore; transtuzumab is adopted as the standard for care in early breast cancer.

Comparisons between studies related to cardiotoxicity are difficult as they used different criteria for assessing cardiac function. The rate of asymptomatic decline by more than 10% in LVEF ranged from a high of 18% in BCIRG 006, to a low of 3% in HERA.

In HERA incidence of cardiotoxicities were higher in transtuzumab group and more in patients who were treated with cumulative doses of doxorubicin (287 mg/m² vs 257 mg/m² or epirubicin (480 mg/m² Vs 422 mg/m²) and had lower baseline LVEF (55% - 60% Vs. >_ 60% and 60% - 65% Vs >_ 65%).

No association was found between cardiac end points and older age, previous cardiac disease, hyperlipidemia or hypertension.
The Finland Herceptin trial (Fin HER) ,HER -2positive patients who received 9 weeks of transtuzumab infusion showed better rate of 3 years recurrence free survival that the women who do not. No decrease in LVEF or Cardiac failure was observed.

**BRIEF REVIEW OF ARTICLES**

(1) **Reversibility of Transtuzumab**— Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment. Michael S.Ewer et al [6] studied on the patients who developed cardiotoxicity while receiving transtuzumab and they improved on discontinuation of the drug (suggesting its reversible action on cardiac myocytes). The found that the mechanism underlying transtuzumab related cardiotoxicity are different from anthracyclins, in part due to absence of ultrastructural changes (evident on endomyocardial biopsy). Mean recovery time of LVEF was 1.5 months and most of the patients could resume the treatment.

(2) **Heart Remodeling induced by adjuvant transtuzumab**— Containing chemotherapy for breast cancer over expressing human epidermal growth factor receptor type – 2. Prospective study by Piotrowski G etal.[7]. They investigated the cardiac changes that occurred in patients of HER -2 positive breast cancer who received transtuzumab in adjuvant setting and concluded that transtuzumab induces left ventricular and left atrial cavity dilatation together with LV systolic function impairment.

(3) **Transtuzumab related cardiac events in the treatment of Early Breast Cancer**. Fried G, Regev T ,Moskovitz M.. [8].

A retrospective study was performed on the patients of cancer breast HER – 2 positive who received transtuzumab, cardiac events (CE) were observed in 21% patients. There was a significant decrease in LVEF between baseline/ post AC and during transtuzumab treatment (mean LVEF 64.29% vs 61.97%, P < 0.001). Treatment related risk factors were age and interval since last AC. Transtuzumab loading dose did not influence CE rates. Patients who received left chest wall irradiation had significantly increased CE rates vs patients without radiotherapy (p <0.05). Any cardio vascular risk factor caused increased risk though not statistically significant.

Concluded that age and prior Anthracyclins appeared to predict the cardiotoxic event hence cardiac monitoring seems important for all patients during treatment with transtuzumab especially in elderly.

(4) **Adjuvant trastuzumab cardiotoxicity in patients over 60years of age with early breast cancer, a multicentric cohort analysis.** [10]
L. Tarantini et al analysed 499 HER 2 +ve early breast cancer patients who were treated with adjuvant transtuzumab and chemotherapy at 10 Italian institutions. They evaluated disease prevalence and patient characteristics in patients over 60 years of age and prevalence of transtuzumab and chemotherapy cardio toxicity and risk factors. They concluded that 32% of HER 2 positive EBC patients treated with transtuzumab chemotherapy are ‘over 60’. These patients have increased cardiovascular risk profile and develop a transtuzumab chemotherapy cardiotoxicity commonly.

(5) Early increases in multiple Biomarkers Predict Subsequent cardiotoxicity in Breast Cancer patients treated with Doxorubicin, Taxanes and transtuzumab. by Ky B et al.

They found that early increases in Troponin I and MPO (myelo-peroxidase) offer additive information about cardio toxicity risk in patients undergoing doxorubicin and transtuzumab therapy.

ARTICLE SUMMARY

The article states that they reviewed the records of elderly breast cancer patients >_ 70 years of age who were treated with transtuzumab since 2006. NYHA classification was used to define symptomatic cardiotoxicity.[25] Asymptomatic cardiotoxicity was defined as an absolute drop of LVEF by >_ 20% or a drop of >_ 10% with final LVEF < 50%. They studied 45 patients of median age 75.9 years, of them, 12.5% patients of early breast cancer and 23.8% patients with advanced disease experienced asymptomatic cardiotoxicity. 8.9% patients developed symptomatic congestive heart failure were all with advanced breast cancer. All the patients except one recovered in a median time of 5 weeks. They concluded that elderly breast cancer patients treated with transtuzumab have an increased incidence of cardiotoxicties as they have history of cardiac disease and/or diabetes. They have advised for continuous cardiac monitoring in this group of patients.

ARTICLE STRUCTURE

The article is well written. It has short paragraphs with bold headings. This makes it easy to comprehend.

The article starts with an abstract which tells us in nutshell the subject and the outcome of the study. It also tells us the background behind the study. It has an introduction which sites the brief concept of HER-2 receptor and transtuzumab. The mechanism of action of transtuzumab induced cardiotoxicity is due to blockade of HER – 2 signaling which is responsible for growth, repair
and survival of cardio myocytes [12]. A large review of advanced breast cancer patients showed increased risk of cardiac events in patients receiving concomitant trastuzumab and anthracyclinc derivative plus cyclophosphamide ~ 27% and a substantially lower risk in patients treated with paclitaxel and trastuzumab ~ 13% or with trastuzumab alone ~ 3-7%. Other major risk factors for trastuzumab related cardiotoxicity is age > 60 years, lower baseline LVEF [4, 14] and prior anthracyclinc exposure.

Next paragraph describes about patients and methods. It says detail about the patients inclusion criteria and exclusion criteria. Definition of cardiotoxicity assessment is clear LVEF assessed either by MUGA scan or by echocardiography [16]. Cardiac events were classified according to NYHA system to document symptomatic CE. [17] Definition of asymptomatic cardiotoxicity is clear.

Results of the retrospective study is described in detail. 26.7% of patients experienced cardiac events. 17.8% developed asymptomatic LVEF decline and 8.9% developed symptomatic congestive heart failure (CHF). All the patients recovered completely after discontinuation of trastuzumab over a median time of 6 weeks. After reversal of LVEF, treatment was restarted with trastuzumab. Only one patient had repeat asymptomatic fall in LVEF which completely recovered without discontinuation of the drug.

All the patients with symptomatic CHF presented with rapidly progressive (< 10 days) dyspnoea and orthopnea. Echocardiography, 2 D ECHO and chest X-ray were used to diagnose CHF. Patients presenting with cardiac events (symptomatic or asymptomatic ) were more often had cardiovascular risk factors. They also were associated with overweight BMI > 30 (P = 0.045), history of previous cardiac event ( P = 0.047) and diabetes mellitus (P = 0.017).

This was followed by discussion and conclusion. In all the breast cancer patients who over express HER – 2 neu receptors, trastuzumab is the standard of care [18,19]. Since incidence of cancer is increasing with age and nearly 70% of newly diagnosed cancer are > 65 years of age [20], elderly cancer patients are expected to increase in the coming years. So, the information of efficacy and safety of anticancer treatment is needed especially in this subgroup of patients who are mostly excluded from pivotal studies. [15, 21] Hence, this study aimed to assess cardiac safety profile and potential cardiac risk factors associated with trastuzumab treatment in patients > 70 years.

The study showed that overall incidence of cardiac events ~26.7% and symptomatic CE in 8.9% cases. Most of the cases(91.7%) are reversible. The results were slightly higher than that reported in trastuzumab pivotal trials [4,5]. This discordance is due to the characteristics of patient population- age and comorbidities. Authors said that their findings were more consistent with that from M D Anderson Cancer Centre than those from pivotal studies.
Authors concluded that there is significant increase in incidence of cardiac events in those patients who had history of cardiac disease &/ or diabetes. Hypertension and smoking history were not demonstrated to increase trastuzumab related cardiotoxicity. Transtuzumab safety profile among elderly breast cancer patients are similar to already reported in earlier studies [13], high proportion of reversibility and safety on retreatment [14, 6] and lack of association between trastuzumab dose [14] and left sided radiotherapy [22] and cardiotoxicity.

Authors also mentioned that there is need for close surveillance of early symptoms and cardiac function in elderly breast cancer patients treated with trastuzumab and to refer them to cardiologist if one or more cardiovascular risk factors are present before or during the treatment with trastuzumab for careful monitoring by multidisciplinary team.

The style of writing is concise and fluid. It serves the purpose of transferring basic aim of study and suggests that further prospective clinical trial are awaited to have more cardiac safety data in elderly population. It also suggest that troponin I level might help to establish diagnosis and prognosis in such patients [24,25].

The article is supported by well documented and acclaimed references.

ARTICLE CRITIQUE

AUTHORITY

The authors are from Breast Cancer Centre, Department of Medical Oncology Vall d’ Hebron University Hospital Barcelona, Spain. The lead author C. Secrano is heading the department. The co-authors are working in the same faculty.

ACCURACY

The authors have tried to be accurate. They have referred to relevant articles published in various journals like New England Journal, Journal of Clinical Oncology. These articles throw light on the main side effect of trastuzumab - cardiotoxicity – rate of incidence, mechanism of action and reversibility on discontinuation of the drug, so this article is accurate. It is unique in the sense that it has studied cardiotoxicity related to trastuzumab in elderly population which are usually underrepresented in most of the clinical trials. Moreover it will also stimulate more clinical trials to include such patients based on their conclusions which will prove accuracy of the study in a prospective way.
CURRENCY

The article is current as there has been no similar study in the past. There has been multiple studies in younger patients which highlights the cardiotoxic effects of transtuzumab and its reversible action.

RELEVANCE

The article is relevant because the incidence of cancer is greatly increasing with age and almost 70% of newly diagnosed cancer patients are in age group >65 years [20] so the study is very much relevant as it has focused on the cardiotoxicity related to transtuzumab treatment in the elderly patients who mostly have one or more cardiovascular risk factors.

OBJECTIVITY

The information in this article has been taken with the objective to analyse the risk of cardiac events in relation to treatment with transtuzumab in elderly breast cancer patients who generally are predisposed with one or more cardiovascular risk factors.

STABILITY

The fact that this article is published in the Annals of Oncology speaks by itself the stability of the article.

ANALYSIS OF GRAPH / IMAGE / TABLE

Table 1- gives details of patient demographics- number of patients in various age subgroups, ECOG performance states, stage of the disease, histological type and their baseline LVEF.

Table 2 - shows details of LVEF variation (symptomatic or asymptomatic) cardiac events distributed by stage of the disease per patients.

Table 3 – gives univariate and multivariate analysis of Cardiac Risk Factors (CRF). Comprehensive analysis of CRF and transtuzumab related cardiac toxicity in an elderly breast cancer population suggest a significant increase in incidence of CE among patients with a history of cardiac disease and diabetes. Other factors like hypertension and smoking history do not relate to increase in cardiotoxicity though the data interpreted is by a small sample size.
RECENT ADVANCES RELATED TO THE TOPIC

Data obtained from this study can serve to advise clinicians to be cautious while administering trastuzumab in elderly, Her-2 positive breast cancer patients especially when they have one or more CRF. It is the first kind of its study that may stimulate further prospective studies involving elderly patients to prove more accurate data with respect to trastuzumab related cardiotoxicity.

CONCLUSION

Trastuzumab can be safely administered in elderly patients with strict surveillance and monitoring of LVEF before and during trastuzumab treatment. The fact that mortality rate at 5 years after diagnosis of CHF is ~50% in patients > 65 years [23], it is necessary to monitor early symptoms and cardiac function in trastuzumab treated elderly patients. Hence, can be referred to cardiologist for prompt management of early symptoms in such patients

REFERENCES


